Future tests

One Platform

Multiple Diagnostic Tests

microscope-tsp-min

Phase 1 Diagnostic Tests

The Biosensor Platform uses Organic Thin Film Transistor (OTFT) technology, which can be printed at scale and low cost. By substituting the detection element (region A), depending on the analyte to be detected, the Biosensor can be modified to monitor a wide range of saliva-based diagnostic analytes. The Platform is being developed to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. We are currently developing two urgently needed innovations using the Biosensor Platform.

Future Pipeline

IMMUNOLOGY

The pilot diagnostic test will be SARS-CoV-2 and the portfolio will consist of various communicable disease tests including Hepatitis A, B & C, HIV and TORCH.

HORMONES

The first test to be developed from a hormone category is Luteinizing Hormone (LH).

BIOCHEMISTRY
 

The pilot diagnostic test is Saliva Glucose. The diagnostic test portfolio includes Clinical Chemistry Tests (ie. Cholesterol).

IMMUNOLOGY

The pilot diagnostic test will be SARS-CoV-2 and the portfolio will consist of various communicable disease tests including Hepatitis A, B & C, HIV and TORCH.

Biosensor Platform

BIOCHEMISTRY
TUMOR MARKERS
IMMUNOLOGY
HORMONES
NUCLEIC ACIDS
Diagnostic Test Portfolio

Clinical Chemistry Tests (i.e. Cholestrol)

Diagnostic and Staging Cancer Markers

Clinical

Immunology Tests

TORCH

HIV, AIDS

Hep A,B & C

Thyroid

Adrenal

Pituitary

Gyncecological

Andrology

Personalised Genetic Diagnostics

Phase 2: Diagnostic Test

Prostate Specific Antigen (PSA)

Luteinizing Hormons (LH)

Phase 1: Diagnostic Test

Saliva Glucose Test

SARS-CoV-2 Antibodies